Global Single-Use Filtration Assemblies Market to Reach $8.1 Billion by 2028, Driven by a CAGR of 17.8%

The global single-use filtration assemblies market is poised for substantial growth, with an expected value of $8.1 billion by 2028, marked by a remarkable Compound Annual Growth Rate (CAGR) of 17.8% during the forecast period.

Single-use filtration assemblies, which ensure sterile fluid flow for pharmaceutical products, offer significant advantages, including reduced cross-contamination risks, enhanced cost-effectiveness, and seamless integration of various components into ready-to-use solutions.

Diverse Applications and Reduced Contamination Risks

Single-use filtration assemblies are vital components linking equipment and instruments in laboratories and the medical field. These assemblies are categorized into filtration assemblies, bottle assemblies, bag assemblies, and mixing system assemblies. Filtration assemblies, a key segment of this market, are utilized for vacuum filtering various aqueous solutions, biological fluids, tissue culture medium, and other applications, effectively removing particle debris through a porous medium.

Market Growth Drivers

  1. Rapidly Evolving Biopharmaceutical Industry: The biopharmaceutical sector has exhibited remarkable growth compared to the pharmaceutical industry, with continued expansion anticipated. Factors contributing to this growth include an aging population, a rise in chronic diseases, and increasing cases of conditions like diabetes, cancer, and autoimmune diseases. The biopharmaceutical industry’s growth fuels the demand for single-use filtration assemblies, particularly in research and production.
  2. Emerging Medical Outsourcing Trend: Healthcare organizations are increasingly outsourcing services to reduce operational costs, enhance efficiency, and improve service quality. Medical outsourcing encompasses diverse functions, including research and manufacturing, medical record management, administrative tasks, customer engagement, and clinical transformation. This trend contributes to market expansion as businesses seek cost-effective solutions.

Market Challenges

  1. Leachables and Extractables Concerns: One of the main challenges in the single-use filtration assemblies market is addressing lower detection limits for leachables and extractables. Detecting low levels of these substances requires advanced mass spectrometry equipment and expertise. Formulation interference in product formulation can also complicate the detection of lower levels, especially in complex matrices.

Key Market Segments:

  • Application: The market serves various applications, including bioprocessing/biopharmaceuticals, pharmaceuticals manufacturing, and laboratory use.
  • Type: Different filtration types include membrane filtration, tangential flow filtration (TFF), depth filtration, centrifugation, and others.
  • Product: Products in the market include filters, membranes, cassettes, cartridges, manifold systems, syringes, and more.

Companies Mentioned

  • 3M Company
  • Sartorius AG
  • Repligen Corporation
  • Merck Millipore (Merck Group)
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • Meissner Filtration Products, Inc.
  • Cellab CDMO
  • Medela AG
  • DrM, Dr. Mueller AG

For more information about this report visit here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.